Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 410-418

  Ranjan, A ^a,b   Schmidt, S ^a,b   Madsbad, S ^a,c   Holst, J J ^c,d   Norgaard K ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b DANISH DIABETES ACADEMY   (Denmark)

^c Capital Region   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Blood pressure; Counter regulation; Dose response relationship; Glucagon; Heart rate; Hypoglycaemia; Pharmacodynamics; Phrmakokinetics; Side effects; Type 1 diabetes

Indexed keywords

FATTY ACID; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; INSULIN ASPART; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FATIGUE; FATTY ACID BLOOD LEVEL; FEEDING DISORDER; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HEART RATE; HEMODYNAMICS; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MALE; NAUSEA; STOMACH PAIN; SWEAT GLAND DISEASE; SYSTOLIC BLOOD PRESSURE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; INSULIN INFUSION; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN ANTAGONISTS; INSULIN ASPART; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84959920256     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12627     Document Type: Article

References (48)

1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-948.
2. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
3. EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 1999; 22: 99-111.
4. Cengiz E, Xing D, Wong JC et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr Diabetes 2013; 14: 447-454.
5. Miller KM, Foster NC, Beck RW et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015; 38: 971-978.
6. Conway B, Miller RG, Costacou T et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 2010; 27: 398-404.
7. DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995; 18: 1415-1427.
8. Fulcher G, Singer J, Castañeda R et al. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. J Med Econ 2014; 17: 751-761.
9. Leiter LA, Yale JF, Chiasson J et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005; 29: 1-7.
10. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D exchange clinic registry. J Clin Endocrinol Metab 2012; 97: 4383-4389.
11. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; 2: CD009122.
12. Reiband HK, Schmidt S, Ranjan A, Holst JJ, Madsbad S, Nørgaard K. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes mellitus. Diabetes Metab Res Rev 2014; 34: 3-12.
13. Hilsted J, Jensen SB. A simple test for autonomic neuropathy in juvenile diabetics. Acta Med Scand 1979; 205: 385-387.
14. Scheen AJ, Castillo MJ, Lefèbvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996; 22: 397-406.
15. Schmidt S, Norgaard K. Bolus calculators. J Diabetes Sci Technol 2014; 8: 1035-1041.
16. Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol 2011; 5: 129-135.
17. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24: 643-645.
18. Wewer Albrechtsen NJ, Hartmann B, Veedfald S et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 2014; 57: 1919-1926.
19. Lindström T, Hedman CA, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Diabetes Care 2002; 25: 1049-1054.
20. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50: 257-259.
21. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal- source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci 1999; 88: 991-995.
22. El Youssef J, Castle JR, Bakhtiani PA et al. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care 2014; 37: 3054-3060.
23. Blauw H, Wendl I, DeVries JH, Heise T, Jax T. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Diabetes Obes Metab 2015; 18: 34-39.
24. Castle JR, El Youssef J, Bakhtiani PA et al. Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system. Diabetes Care 2015; 38: 2115-2119.
25. Christensen M, Calanna S, Sparre-Ulrich AH et al. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes 2015; 64: 72-78.
26. Højbjerg Gravholt C, Møller N, Jensen MD, Christiansen JS, Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab 2001; 86: 2085-2089.
27. Xiao C, Pavlic M, Szeto L, Patterson BW, Lewis GF. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 2011; 60: 383-390.
28. Méry PF, Brechler V, Pavoine C, Pecker F, Fischmeister R. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 1990; 345: 158-161.
29. Krutý F, Gvozdják A, Bada V, Niederland TR, Gvozdják J, Kaplán M. The effect of glucagon on the heart muscle: relation between metabolic processes and contractility. Biochem Pharmacol 1978; 27: 2153-2155.
30. Murtagh JG, Binnion PF, Lal S, Hutchison KJ, Fletcher E. Haemodynamic effects of glucagon. Br Heart J 1970; 32: 307-315.
31. Albisser AM, Leibel BS, Ewart TG et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23: 397-404.
32. Schmidt S, Boiroux D, Ranjan A, Jørgensen JB, Madsen H, Nørgaard K. An artificial pancreas for automated blood glucose control in patients with type 1 diabetes. Ther Deliv 2015; 6: 609-619.
33. Castle JR, Engle JM, El Youssef J et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33: 1282-1287.
34. Russell S, El-Khatib F. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012; 35: 2148-2155.
35. Leelarathna L, Nodale M, Allen JM et al. Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems. Diabetes Technol Ther 2013; 15: 143-149.
36. Haidar A, Legault L, Matteau-Pelletier L et al. Outpatient overnight glucose control with dual-hormone artifi cial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2015; 3: 595-604.
37. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015; 3: 17-26.
38. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010; 2: 1-12.
39. Bakhtiani PA, El Youssef J, Duell AK et al. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. J Diabetes Complications 1964; 2014: 2010-2015.
40. Hinshaw L, Mallad A, Dalla Man C et al. Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments. Am J Physiol Endocrinol Metab 2015; 309: E474-E486.
41. DeFronzo RA, Andres R, Bedsoe TA, Boden G, Faloona GA, Tobin JD. A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. Diabetes 1977; 26: 445-452.
42. Lilavivathana U, Brodows RG, Woolf PD, Campbell RG. Counterregulatory hormonal responses to rapid glucose lowering in diabetic man. Diabetes 1979; 28: 873-877.
43. Amiel SA, Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans. Diabetes 1987; 36: 518-522.
44. Lv D, Breton MD, Farhy LS. Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. Diabetes Technol Ther 2013; 15: 935-941.
45. Haidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol 2013; 7: 1507-1512.
46. Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol 2010; 4: 1357-1367.
47. Pohl R, Li M, Krasner A, De Souza E. Development of stable liquid glucagon formulations for use in artificial pancreas. J Diabetes Sci Technol 2015; 9: 8-16.
48. Rickels MR, Ruedy KJ, Foster NC et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 2015; 39: 264-270.